$17.97
6.39% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US92790C1045
Symbol
VRDN

Viridian Therapeutics Inc Stock price

$17.97
+0.83 4.84% 1M
+0.50 2.86% 6M
-1.20 6.26% YTD
+2.68 17.53% 1Y
+3.24 22.00% 3Y
+1.02 6.02% 5Y
-335.64 94.92% 10Y
-2,027.28 99.12% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+1.08 6.39%
ISIN
US92790C1045
Symbol
VRDN
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$797.5m
Net debt
positive
Cash
$563.4m
Shares outstanding
81.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4,322.8 | 6,623.3
EV/Sales
2,572.6 | 3,941.7
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
90.5%
Return on Equity
-40.2%
ROCE
-70.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$310.0k | $202.3k
EBITDA
$-371.1m | $-336.4m
EBIT
$-371.6m | $-385.8m
Net Income
$-344.1m | $-329.2m
Free Cash Flow
$-309.6m
Growth (TTM | estimate)
Revenue
6.9% | -32.6%
EBITDA
-48.3% | -12.7%
EBIT
-48.2% | -29.0%
Net Income
-50.9% | -22.0%
Free Cash Flow
-83.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-121,672.8% | -166,285.8%
EBIT
-121,831.2%
Net
-112,806.9% | -162,704.4%
Free Cash Flow
-101,507.9%
More
EPS
$-4.2
FCF per Share
$-3.8
Short interest
14.9%
Employees
94
Rev per Employee
$0.0
Show more

Is Viridian Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Viridian Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Viridian Therapeutics Inc forecast:

19x Buy
86%
3x Hold
14%

Analyst Opinions

22 Analysts have issued a Viridian Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Viridian Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.31 0.31
7% 7%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 67 67
21% 21%
21,713%
- Research and Development Expense 305 305
83% 83%
98,252%
-371 -371
48% 48%
-119,710%
- Depreciation and Amortization 0.48 0.48
16% 16%
155%
EBIT (Operating Income) EBIT -372 -372
48% 48%
-119,866%
Net Profit -344 -344
51% 51%
-110,987%

In millions USD.

Don't miss a Thing! We will send you all news about Viridian Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viridian Therapeutics Inc Stock News

Neutral
The Motley Fool
6 days ago
Viridian (VRDN) Q2 Net Loss Widens 55%
Neutral
Business Wire
7 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2025. “Veligrotug's recent Breakthrough Therapy Designation as well as the...
Neutral
Business Wire
9 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock o...
More Viridian Therapeutics Inc News

Company Profile

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Head office United States
CEO Stephen Mahoney
Employees 94
Founded 2006
Website www.viridiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today